New FDA guidance on addressing misinformation under White House review

BY LAURA DIANGELO, MPH

A new question-and-answer draft guidance document focused on “addressing misinformation” about regulated life sciences products is currently under administrative review at the White House’s Office of Information and Regulatory Affairs (OIRA). The new draft document comes as FDA leadership has been flagging concerns about misinformation, including in public testimony and reports.

Fill out the form to read the full article.